A 67-year-old Chinese woman presented to the emergency department with a three-day history of nausea and vomiting, palpitations and chest discomfort. Her symptoms had started suddenly a few hours after eating lunch, beginning with generalized weakness and fatigue; she had noticed that her pulse was slow and irregular. A few hours later, chest pressure developed along with abdominal cramping associated with nausea and vomiting, which persisted.

The patient’s medical history included hypertension, dyslipidemia, Meniere disease and asthma. She was not taking prescription medications; supplements included vitamin B12, glucosamine and Chinese herbs (prepared licorice, dried rehmannia root, cinnamon twig, *Ophiopogon japonicus*, *ejiao*, hemp seed, jujube and ginger). Her vital signs were notable for bradycardia (53 beats/min); other findings on physical examination were normal.

Results of initial laboratory investigations, including electrolyte levels, renal function, liver biochemistry and synthetic function, were normal. Her serum potassium level was 4.1 (normal 3.5–5.0) mmol/L and magnesium level 0.96 (normal 0.70–1.10) mmol/L. Complete blood count revealed a slightly elevated leukocyte count (14.0 × 10^9/L). Serial troponin levels were not elevated. An ECG showed sinus bradycardia with nonspecific ST-segment changes and lateral T-wave inversion; there was no previous ECG for comparison. In the emergency department, the husband was noted to have episodes of bradycardia, with a heart rate in the 30s. Both patients reported visual disturbances, described as flashing lights and yellow/red halos around objects.

On further questioning, the wife revealed they had consumed a bitter-tasting leafy green plant on the day her symptoms began. Her husband had picked the leaves from their vegetable garden, believing them to be kale. Given the constellation of symptoms in both patients following this meal, a toxic ingestion seemed likely.

Serum digoxin levels, normally undetectable, were 0.3 nmol/L in the wife and 0.4 nmol/L in the husband. The family brought in plant specimens from their garden (Figure 2), which were later confirmed to be foxglove (*Digitalis purpurea*).

Cases

Two cases of cardiac glycoside poisoning from accidental foxglove ingestion

Renée M. Janssen MD MSc, Mattias Berg MD, Daniel H. Ovakim MD MSc

Cardiac glycoside toxicity is primarily a clinical diagnosis and should be suspected in patients presenting with nausea, vomiting, hyperkalemia and unexplained cardiac arrhythmias.

The local poison control centre should be contacted in all suspected or confirmed cases of cardiac glycoside toxicity.

In poisonings from nonpharmaceutical cardiac glycosides, quantitative serum digoxin levels do not correlate with measurements of these toxins and cannot be used to calculate the dose of digoxin-specific antibody fragments (digoxin-Fab).

Serum digoxin levels should not be measured following administration of digoxin-Fab owing to interference with the immunoassay.
Once the diagnosis of cardiac glycoside toxicity was confirmed and the provincial poison control centre was consulted, both patients were given digoxin-Fab. The husband initially received 5 vials, and his wife, whose symptoms were more severe, received 10 vials. Both patients experienced considerable improvement in symptoms within an hour after receiving the antidote. Over the course of the next several days, they were each administered a total of 12 vials. Both patients experienced complete resolution of their symptoms and were discharged home.

Discussion

Foxglove (including *D. purpurea* and *Digitalis lanata*) is one of many plants containing cardiac glycosides that exert potent inotropic and electrochemical effects on cardiac tissue. Hundreds of cardiac glycosides have been isolated from plants across 12 botanical families, including members of the *Digitalis* genus (foxglove), *Cascabela thevetia* (yellow oleander) and *Convallaria majalis* (lily of the valley). The cardiac glycosides of medical importance are extracted from *D. purpurea* and *D. lanata*, yielding digitoxin and digoxin, respectively.

Foxglove (Figure 3) is native to Europe and widely naturalized to temperate climes in North America, including Canada. Accidental ingestion of foxglove is uncommon because of its distinctive flowers and bitter taste. However, the plant does not flower in its first year, and the rosette of basal leaves of the juvenile plant has been mistaken for borage¹ or comfrey.² In British Columbia, the two cases we have described here constitute the only cases of symptomatic cardiac glycoside poisoning from plant ingestion requiring antidote.

---

**Figure 1**: Electrocardiogram (ECG) strips from lead II (A through D) and leads II and V1 (E), showing the progression of ECG changes in a 67-year-old woman during her hospital admission, before administration of digoxin immune antibody fragments. (A) Admission ECG shows sinus rhythm with first-degree atrioventricular block (PR interval 210 ms) and sinus pauses. (B) ECG later on day 1 shows sinus bradycardia (heart rate 45 beats/min); PR interval has returned to normal (166 ms). (C) ECG on day 2 shows accelerated junctional rhythm with P waves and atrioventricular dissociation (complete heart block). (D) ECG on day 3 shows sinus bradycardia with nonspecific ST-segment changes and ST-segment depression. (E) ECG from telemetry strip on day 4 of admission shows monomorphic ventricular tachycardia, which lasted for about 30 seconds and was self-limited.
Pharmaceutical cardiac glycoside toxicity

Cardiac glycosides, such as digoxin, have long been used to improve inotropy in patients with congestive heart failure, and to slow ventricular rates in patients with atrial fibrillation or flutter. Although the therapeutic range for digoxin is 0.64–1.28 nmol/L, cardiotoxicity has been reported in patients maintained within this range, particularly those receiving long-term treatment. Serum digoxin levels, and the risk of subsequent toxicity, are highly susceptible to changes in renal function, serum potassium levels (hypokalemia), concurrent use of medications that interfere with digoxin excretion (e.g., amiodarone and non-dihydropyridine calcium-channel blockers) and genetic polymorphisms that impair the activity of P-glycoprotein.6 Digoxin toxicity should be suspected and treated in patients who present with consistent clinical features regardless of their serum digoxin level (Box 2).

Diagnosis

Cardiac glycoside toxicity is primarily a clinical diagnosis. Serum digoxin levels should be obtained to confirm the diagnosis and to guide antidote administration (in the context of pharmaceutical digoxin poisoning).8 Although there is cross-reactivity with other cardiac glycosides, the digoxin immunoassay is specific for the detection of digoxin. Because of unpredictable cross-reactivity, the quantitative value has no relation to the degree of toxicity from exposure to nonpharmaceutical cardiac glycosides, and may even be undetectable.8 The serum digoxin level should therefore not be used to guide antidote dosage in cases of nonpharmaceutical cardiac glycoside ingestion.

Pharmaceutical cardiac glycoside toxicity

Cardiac glycosides, such as digoxin, have long been used to improve inotropy in patients with congestive heart failure, and to slow ventricular rates in patients with atrial fibrillation or flutter. Although the therapeutic range for digoxin is 0.64–1.28 nmol/L, cardiotoxicity has been reported in patients maintained within this range, particularly those receiving long-term treatment. Serum digoxin levels, and the risk of subsequent toxicity, are highly susceptible to changes in renal function, serum potassium levels (hypokalemia), concurrent use of medications that interfere with digoxin excretion (e.g., amiodarone and non-dihydropyridine calcium-channel blockers) and genetic polymorphisms that impair the activity of P-glycoprotein.6 Digoxin toxicity should be suspected and treated in patients who present with consistent clinical features regardless of their serum digoxin level (Box 2).

Diagnosis

Cardiac glycoside toxicity is primarily a clinical diagnosis. Serum digoxin levels should be obtained to confirm the diagnosis and to guide antidote administration (in the context of pharmaceutical digoxin poisoning).8 Although there is cross-reactivity with other cardiac glycosides, the digoxin immunoassay is specific for the detection of digoxin. Because of unpredictable cross-reactivity, the quantitative value has no relation to the degree of toxicity from exposure to nonpharmaceutical cardiac glycosides, and may even be undetectable.8 The serum digoxin level should therefore not be used to guide antidote dosage in cases of nonpharmaceutical cardiac glycoside ingestion.

Pharmaceutical cardiac glycoside toxicity

Cardiac glycosides, such as digoxin, have long been used to improve inotropy in patients with congestive heart failure, and to slow ventricular rates in patients with atrial fibrillation or flutter. Although the therapeutic range for digoxin is 0.64–1.28 nmol/L, cardiotoxicity has been reported in patients maintained within this range, particularly those receiving long-term treatment. Serum digoxin levels, and the risk of subsequent toxicity, are highly susceptible to changes in renal function, serum potassium levels (hypokalemia), concurrent use of medications that interfere with digoxin excretion (e.g., amiodarone and non-dihydropyridine calcium-channel blockers) and genetic polymorphisms that impair the activity of P-glycoprotein.6 Digoxin toxicity should be suspected and treated in patients who present with consistent clinical features regardless of their serum digoxin level (Box 2).

Diagnosis

Cardiac glycoside toxicity is primarily a clinical diagnosis. Serum digoxin levels should be obtained to confirm the diagnosis and to guide antidote administration (in the context of pharmaceutical digoxin poisoning).8 Although there is cross-reactivity with other cardiac glycosides, the digoxin immunoassay is specific for the detection of digoxin. Because of unpredictable cross-reactivity, the quantitative value has no relation to the degree of toxicity from exposure to nonpharmaceutical cardiac glycosides, and may even be undetectable.8 The serum digoxin level should therefore not be used to guide antidote dosage in cases of nonpharmaceutical cardiac glycoside ingestion.

Pharmaceutical cardiac glycoside toxicity

Cardiac glycosides, such as digoxin, have long been used to improve inotropy in patients with congestive heart failure, and to slow ventricular rates in patients with atrial fibrillation or flutter. Although the therapeutic range for digoxin is 0.64–1.28 nmol/L, cardiotoxicity has been reported in patients maintained within this range, particularly those receiving long-term treatment. Serum digoxin levels, and the risk of subsequent toxicity, are highly susceptible to changes in renal function, serum potassium levels (hypokalemia), concurrent use of medications that interfere with digoxin excretion (e.g., amiodarone and non-dihydropyridine calcium-channel blockers) and genetic polymorphisms that impair the activity of P-glycoprotein.6 Digoxin toxicity should be suspected and treated in patients who present with consistent clinical features regardless of their serum digoxin level (Box 2).

Diagnosis

Cardiac glycoside toxicity is primarily a clinical diagnosis. Serum digoxin levels should be obtained to confirm the diagnosis and to guide antidote administration (in the context of pharmaceutical digoxin poisoning).8 Although there is cross-reactivity with other cardiac glycosides, the digoxin immunoassay is specific for the detection of digoxin. Because of unpredictable cross-reactivity, the quantitative value has no relation to the degree of toxicity from exposure to nonpharmaceutical cardiac glycosides, and may even be undetectable.8 The serum digoxin level should therefore not be used to guide antidote dosage in cases of nonpharmaceutical cardiac glycoside ingestion.

Pharmaceutical cardiac glycoside toxicity

Cardiac glycosides, such as digoxin, have long been used to improve inotropy in patients with congestive heart failure, and to slow ventricular rates in patients with atrial fibrillation or flutter. Although the therapeutic range for digoxin is 0.64–1.28 nmol/L, cardiotoxicity has been reported in patients maintained within this range, particularly those receiving long-term treatment. Serum digoxin levels, and the risk of subsequent toxicity, are highly susceptible to changes in renal function, serum potassium levels (hypokalemia), concurrent use of medications that interfere with digoxin excretion (e.g., amiodarone and non-dihydropyridine calcium-channel blockers) and genetic polymorphisms that impair the activity of P-glycoprotein.6 Digoxin toxicity should be suspected and treated in patients who present with consistent clinical features regardless of their serum digoxin level (Box 2).

Diagnosis

Cardiac glycoside toxicity is primarily a clinical diagnosis. Serum digoxin levels should be obtained to confirm the diagnosis and to guide antidote administration (in the context of pharmaceutical digoxin poisoning).8 Although there is cross-reactivity with other cardiac glycosides, the digoxin immunoassay is specific for the detection of digoxin. Because of unpredictable cross-reactivity, the quantitative value has no relation to the degree of toxicity from exposure to nonpharmaceutical cardiac glycosides, and may even be undetectable.8 The serum digoxin level should therefore not be used to guide antidote dosage in cases of nonpharmaceutical cardiac glycoside ingestion.
Management
The management of cardiac glycoside poisoning includes supportive care and antidote therapy with digoxin-specific antibody fragments (digoxin-Fab). Digoxin-Fab is indicated for severe cases of cardiac glycoside toxicity (Box 2). It should be avoided in milder cases because of the theoretical risk of immunogenicity. Currently available commercial preparations include DigiFab and DigiBind (the latter of which is unavailable in North America); each vial, administered intravenously, binds 0.5 mg of digoxin. Following administration of digoxin-Fab, serum total digoxin levels should not be measured until the antidote has been eliminated from the body (up to three weeks in patients with impaired kidney function), due to interference with the immunoassay.

Digoxin-Fab has also proven to be effective as an antidote for poisonings from other cardiac glycosides. A randomized controlled trial involving 66 patients with cardiac glycoside toxicity from ingestion of yellow oleander in Sri Lanka found that digoxin-Fab resulted in a significant resolution of dysrhythmias and hyperkalemia compared with saline placebo. Several other observational studies have reported favourable outcomes with use of digoxin-Fab in cases of plant-related cardiac glycoside poisonings. Dosing recommendations for symptomatic nondigoxin cardiac glycoside exposure suggest empiric administration of 10 vials of digoxin-Fab.

References
1. Maffe S, Cucchi L, Zenone F, et al. Digitalis must be banished from the table: a rare case of acute accidental digitalis intoxication of a whole family. J Cardiovasc Med (Hagerstown) 2009;10:727-32.
2. Lin CC, Yang CC, Phua DH, et al. An outbreak of foxglove leaf poisoning. J Chin Med Assoc 2010;73:97-100.
3. Ma G, Brady WJ, Pollack M, et al. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med 2001;20:145-52.
4. Mahdyoon H, Baitllana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J 1990;120:1189-94.
5. Edelstein M, Ariaratnam CA, Sjostrom L, et al. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart 2000;83:301-6.
6. Xu D, Jiang YP, Zhang BK, et al. Impact of MDRI haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 2008;82:221-7.
7. DigiFab [product monograph]. Ottawa: Canadian Pharmacists Association. Available: www.e-cps.ca (accessed 2015 May 11).
8. Smith TW, Anntam EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiol 1984;26:413-58.
9. Edelstein M, Rajapakse S, Rajakanthan K, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000;355:967-72.
10. Roberts DM, Buckley NA. Antidotes for acute cardenolide (cardiac glycoside) poisoning. Cochrane Database Syst Rev 2006; (4):CD005490.

Affiliations: Departments of Medicine (Janssen, Ovakim) and Emergency Medicine (Berg), University of British Columbia; British Columbia Drug and Poison Information Centre (Ovakim), Vancouver, BC

Contributors: Renée Janssen drafted the manuscript. All of the authors contributed equally to the revising of the manuscript, gave final approval of the version to be published and agreed to act as guarantors of the work.